ABL Diagnostics (XPAR:ABLD) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:ABLD ABL Diagnostics XPAR:ABLD
50 GF Score
Price €2.46
GF Value €7.96
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is ABL Diagnostics Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of ABL Diagnostics is: No Data: Cannot be evaluated.

ABL Diagnostics  (XPAR:ABLD) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

ABL Diagnostics Risk Assessment Related Terms

XPAR:ABLD vs VEEV, BTSG, HQY: Risk Assessment Comparison

For the Health Information Services subindustry, ABL Diagnostics's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ABL Diagnostics Risk Assessment vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's Risk Assessment distribution charts can be found below:

* The bar in red indicates where ABL Diagnostics's Risk Assessment falls into.


XPAR:ABLD
50GF Score
ABL Diagnostics XPAR:ABLD
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is ABL Diagnostics (XPAR:ABLD) Overvalued in 2026?

Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued. The current stock price of €2.46 is trading 69.1% below its estimated GF Value™ of €7.96. GuruFocus considers ABL Diagnostics to be Significantly Undervalued.

Key valuation signals for XPAR:ABLD:

  • Risk Assessment:
  • GF Value™: €7.96 vs. price of €2.46 (69.1% below fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the XPAR:ABLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ABL Diagnostics Business Description

Other Exchanges 9BK0:Germany
Address 72c, rue de, WOIPPY, Thionville, FRA, 57140
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
50GF Score

Get the complete analysis for XPAR:ABLD

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.46
Price
€7.96
GF Value